Search

Your search keyword '"CarMeN, laboratoire"' showing total 11 results
Start Over Author "CarMeN, laboratoire" Publisher wiley
11 results on '"CarMeN, laboratoire"'

1. Sex differences in imaging and clinical characteristics of patients from the WAKE--UP trial

Author

Anke Wouters, Lauranne Scheldeman, Hannelore Liessens, Patrick Dupont, Florent Boutitie, Bastian Cheng, Martin Ebinger, Matthias Endres, Jochen B. Fiebach, Christian Gerloff, Keith W. Muir, Norbert Nighoghossian, Salvador Pedraza, Claus Z. Simonsen, Vincent Thijs, Götz Thomalla, Robin Lemmens, University Hospitals Leuven [Leuven], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Leuven Center for Cancer Biology (VIB-KU-CCB), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven)-Vlaams Instituut voor Biotechnologie [Ghent, Belgique] (VIB), Amsterdam UMC - Amsterdam University Medical Center, Leuven Brain Institute [Leuven, Belgium] (LBI), Hospices Civils de Lyon (HCL), Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Medical Park Berlin Humboldtmühle [Berlin, Germany] (MPBH), German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), German Research Center for Neurodegenerative Diseases - Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), University of Glasgow, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta - Girona Biomedical Research Institute (IDIBGI), Aarhus University Hospital, University of Melbourne, Austin Hospital [Melbourne], Austin Health, CarMeN, laboratoire, and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, Sex Characteristics, Time Factors, Ischemic stroke, [SDV.BA] Life Sciences [q-bio]/Animal biology, [SDV.BA]Life Sciences [q-bio]/Animal biology, methods [Thrombolytic Therapy], wake-up, drug therapy [Stroke], therapeutic use [Tissue Plasminogen Activator], Neurology, Wake-up, methods [Diffusion Magnetic Resonance Imaging], diagnostic imaging [Stroke], ischemic stroke, Humans, drug therapy [Brain Ischemia], sex, Female, Sex, ddc:610, Neurology (clinical), Mri, MRI
Abstract

BACKGROUND AND PURPOSE: Sex-based differences in acute ischemic stroke are a well-known phenomenon. We aimed to explore these differences between women and men in the Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke (WAKE-UP) trial. METHODS: We compared baseline demographic and imaging characteristics (visual fluid-attenuated inversion recovery [FLAIR] positivity, relative FLAIR signal intensity, collateral status) between women and men in all screened patients. In randomized patients (i.e., those with diffusion-weighted imaging (DWI)-FLAIR mismatch), we evaluated a modifying role of sex on the treatment effect of alteplase in multivariable logistic regression, with treatment adjusted for National Institute of Health Stroke Scale (NIHSS) score and age. Dependent variables were modified Rankin Scale (mRS) score of 0-1 at 90 days and distribution of mRS scores at 90 days. RESULTS: Of 1362 screened patients, 529 (38.8%) were women. Women were older than men, had higher baseline NIHSS scores and smoked less frequently. FLAIR positivity of the DWI lesion was equally present in women (174/529, 33.1%) and men (273/833, 33.3%; p = 1.00) and other imaging variables also did not differ between the sexes. In a total of 503 randomized patients, of whom 178 were women (35.4%), sex did not modify the treatment effect of alteplase on mRS score 0-1 or on the total distribution of mRS scores. CONCLUSION: As in many other stroke trials, more men than women were included in the WAKE-UP trial, but the presence of a visual DWI-FLAIR mismatch and the relative FLAIR signal intensity did not differ between the sexes. The treatment effect of alteplase was not modified by sex. ispartof: EUROPEAN JOURNAL OF NEUROLOGY vol:30 issue:3 pages:641-647 ispartof: location:England status: published

Published
2023

2. Critically ill patients with severe infections related to Geotrichum species: A French retrospective multicentre study

Author

Nadia Aissaoui, Benoit Champigneulle, Muriel Picard, Michael Darmon, Andrine Valade, Anne Sophie Moreau, Julien Mayaux, Laure Calvet, Etienne de Montmollin, Fabrice Bruneel, Frédéric Pène, Martin Murgier, Florence Boissier, Laurent Argaud, Elie Azoulay, Naïke Bigé, Djamel Mokart, CarMeN, laboratoire, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Cité (UPCité), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier de Versailles André Mignot (CHV), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Sorbonne Paris Cité (USPC), Université Paris Descartes - Paris 5 (UPD5), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre hospitalier universitaire de Poitiers (CHU Poitiers), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Cochin [AP-HP], CHU Pitié-Salpêtrière [AP-HP], Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), CHU Lille, and Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne)

Subjects
Adult, Antifungal, medicine.medical_specialty, multiple organ failure, medicine.drug_class, health care facilities, manpower, and services, [SDV]Life Sciences [q-bio], Critical Illness, Dermatology, Internal medicine, Intensive care, medicine, Humans, Geotrichum species, Hospital Mortality, intensive care, Retrospective Studies, invasive fungal infections, Adult patients, business.industry, Critically ill, Geotrichosis, General Medicine, Middle Aged, Geotrichum, Icu admission, [SDV] Life Sciences [q-bio], Intensive Care Units, Infectious Diseases, Respiratory failure, outcome, SOFA score, France, business
Abstract

International audience; OBJECTIVES: Geotrichum spp can be responsible for severe infections in immunocompromised patients. We aim to describe Geotrichum-related infections in the ICU and to assess risk factors of mortality. METHODS: Retrospective multicentre study, conducted in 14 French ICUs between 2002 and 2018, including critically ill adult patients with proven or probable infection related to Geotrichum species. Data were obtained from the medical charts. RESULTS: Thirty-six patients, median age 60 years IQR [53; 66] were included. Most of the patients had haematological malignancies (78%). The reason for ICU admission was shock in half of the patients (n = 19, 53%) and respiratory failure in thirteen patients (36%). Median SOFA score was 8.5 IQR [7; 15]. Time between ICU admission and fungal diagnosis was 2.5 days [-1; 4]. Infection was disseminated in 27 (75%) patients with positive blood cultures in 25 patients (69%). Thirty patients (83%) received curative antifungal treatment in the ICU, in a median time of 1 day [0;1] after ICU admission. Twenty-four patients (67%) died in the ICU and hospital mortality rate was 69%. The number and extent of organ failures, as represented by SOFA score, were associated with mortality. CONCLUSIONS: This study demonstrates poor outcome in critically ill patients with Geotrichum-related infections, which encourages a high level of suspicion.

Published
2021

3. Fibroblast growth factor 19 as a countermeasure to muscle and locomotion dysfunctions in experimental cerebral palsy

Author

Hubert Vidal, Francisco Carlos Amanajás de Aguiar Júnior, Sabrina da Conceição Pereira, Stéphanie Chanon, Sandra Pesenti, Jérome Ruzzin, Aurélie Vieille-Marchiset, Ana Elisa Toscano, Bérengère Benoit, Federal University of Pernambuco [Recife], Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), University of Oslo (UiO), and CarMeN, laboratoire

Subjects
Male, Sarcopenia, medicine.medical_specialty, Small-Conductance Calcium-Activated Potassium Channels, [SDV]Life Sciences [q-bio], Skeletal muscle, Diseases of the musculoskeletal system, Fibroblast growth factor, Cerebral palsy, Mice, Pregnancy, Physiology (medical), Internal medicine, medicine, Animals, Orthopedics and Sports Medicine, Tibia, Rats, Wistar, Muscle, Skeletal, Fibroblast growth factor 19, business.industry, Cerebral Palsy, QM1-695, FGF19, Original Articles, medicine.disease, Muscle atrophy, Rats, Motor coordination, [SDV] Life Sciences [q-bio], Fibroblast Growth Factors, Endocrinology, medicine.anatomical_structure, RC925-935, Human anatomy, Original Article, Female, medicine.symptom, business, Locomotion
Abstract

International audience; BACKGROUND: Cerebral palsy (CP) associates cerebral function damages with strong locomotor defects and premature sarcopenia. We previously showed that fibroblast growth factor 19 (FGF19) exerts hypertrophic effects on skeletal muscle and improves muscle mass and strength in mouse models with muscle atrophy. Facing the lack of therapeutics to treat locomotor dysfunctions in CP, we investigated whether FGF19 treatment could have beneficial effects in an experimental rat model of CP. METHODS: Cerebral palsy was induced in male Wistar rat pups by perinatal anoxia immediately after birth and by sensorimotor restriction of hind paws maintained until Day 28. Daily subcutaneous injections with recombinant human FGF19 (0.1 mg/kg bw) were performed from Days 22 to 28. Locomotor activity and muscle strength were assessed before and after FGF19 treatment. At Day 29, motor coordination on rotarod and various musculoskeletal parameters (weight of tibia bone and of soleus and extensor digitorum longus (EDL) muscles; area of skeletal muscle fibres) were evaluated. In addition, expression of specific genes linked to human CP was measured in rat skeletal muscles. RESULTS: Compared to controls, CP rats had reduced locomotion activity (-37.8% of distance travelled, P \textless 0.05), motor coordination (-88.9% latency of falls on rotarod, P \textless 0.05) and muscle strength (-25.1%, P \textless 0.05). These defects were associated with reduction in soleus (-51.5%, P \textless 0.05) and EDL (-42.5%, P \textless 0.05) weight, smaller area of muscle fibres, and with lower tibia weight (-38%, P \textless 0.05). In muscles from rats submitted to CP, changes in the expression levels of several genes related to muscle development and neuromuscular junctions were similar to those found in wrist muscle of children with CP (increased mRNA levels of Igfbp5, Kcnn3, Gdf8, and MyH4 and decreased expression of Myog, Ucp2 and Lpl). Compared with vehicle-treated CP rats, FGF19 administration improved locomotor activity (+53.2%, P \textless 0.05) and muscle strength (+25.7%, P \textless 0.05), and increased tibia weight (+13.8%, P \textless 0.05) and soleus and EDL muscle weight (+28.6% and +27.3%, respectively, P \textless 0.05). In addition, it reduced a number of very small fibres in both muscles (P \textless 0.05). Finally, gene expression analyses revealed that FGF19 might counteract the immature state of skeletal muscles induced by CP. CONCLUSIONS: These results demonstrate that pharmacological intervention with recombinant FGF19 could restore musculoskeletal and locomotor dysfunction in an experimental CP model, suggesting that FGF19 may represent a potential therapeutic strategy to combat the locomotor disorders associated with CP.

Published
2021

4. Central hypothyroidism during pregnancy in a woman with Graves' disease

Author

Safouane M. Hamdi, Glinoer Daniel, Tanguy Faustine, Philippe Caron, Chikh Karim, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut Fédératif de Biologie (IFB), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Vrije Universiteit Brussel (VUB), and CarMeN, laboratoire

Subjects
medicine.medical_specialty, Pregnancy, Pediatrics, business.industry, [SDV]Life Sciences [q-bio], Endocrinology, Diabetes and Metabolism, Graves' disease, Pregnancy Complications, medicine.disease, Graves Disease, [SDV] Life Sciences [q-bio], Endocrinology, Hypothyroidism, Internal medicine, medicine, Central hypothyroidism, Humans, Female, business, Graves Disease/complications/drug therapy
Abstract

International audience; No abstract available

Published
2021

5. A systematic review and meta‐analyses of food preference modifications after bariatric surgery

Author

Sarah Bagot, Emmanuel Disse, Erika Guyot, Julie-Anne Nazare, Sylvain Iceta, Anestis Dougkas, Centre Européen Nutrition et Santé [Pierre-Bénite] (CENS/CRNH-RA), Centre de Recherche en Nutrition Humaine Rhône Alpes (CRNH Rhône Alpes), Centre de Recherche de l'Institut Paul Bocuse [Ecully] (CRIPB), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Université Laval [Québec] (ULaval), and CarMeN, laboratoire

Subjects
Sleeve gastrectomy, medicine.medical_specialty, bariatric surgery, [SDV]Life Sciences [q-bio], Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Gastric bypass, Gastric Bypass, MEDLINE, CINAHL, Cochrane Library, Food preference, Food Preferences, Gastrectomy, Food choice, medicine, Humans, business.industry, Public Health, Environmental and Occupational Health, Obesity, Morbid, Surgery, [SDV] Life Sciences [q-bio], food reward, food choices, Observational study, food preference, business
Abstract

International audience; This systematic review and meta-analyses aimed to synthesize evidence of the link between bariatric surgery and changes in food preferences, considering the method of assessment. MEDLINE, Cochrane Library, Web of Science, Cinahl, PsychINFO, ProQuest, and Open grey were searched incorporating two blocks of terms ("Intervention" and "Food Preferences"). Interventional or observational studies involving patients (BMI ≥ 35 kg m(-2) ) with sleeve gastrectomy (SG) or Roux-en-Y Gastric Bypass (RYGB) and a control group were included. Meta-analyses were performed comparing the standardized daily mean percentage energy from proteins, carbohydrates, and lipids between preoperative and postoperative patients. Fifty-seven studies concerning 2,271 patients with RYGB and 903 patients with SG met the inclusion criteria, of which 24 were eligible for meta-analysis. Despite a total reduction in macronutrient intakes, the meta-analyses revealed a postoperative increase in percentage energy from proteins at 12 months (0.24, 95% CI: 0.03, 0.46, \I(2) \ = 73%) and a decrease in percentage energy from fat at 1 month (-0.47, 95% CI: 0.86, 0.09, \I(2) \ = 72%), up to 24 months (-0.20, 95% CI: -0.31, 0.08, \I(2) \ = 0%). In conclusion, the present systematic review and meta-analyses showed changes of food preferences in terms of macronutrient, food selection and, overall food appreciation up to 5 years following bariatric surgery.

Published
2021

6. Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial

Author

Bastian Cheng, Salvador Pedraza, Keith W. Muir, Florent Boutitie, Matthias Endres, Alina Königsberg, Robin Lemmens, Sönke Arlt, Susanne Sehner, Christian Gerloff, Jochen B. Fiebach, Claus Z Simonsen, Vincent Thijs, Götz Thomalla, Martin Ebinger, Norbert Nighoghossian, Joaquín Serena, CarMeN, laboratoire, University Hospital Hamburg-Eppendorf, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Evangelisches Krankenhaus Alsterdorf [Hamburg, Germany] (EKA), Aarhus University Hospital, Hospices Civils de Lyon (HCL), Girona Biomedical Research Institute [Girona, Spain] (IDIBGI), Austin Health, University of Melbourne, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University Hospitals Leuven [Leuven], Vesalius Research Center [Louvain, Belgique], University of Glasgow, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and WAKE-UP investigators

Subjects
[SDV]Life Sciences [q-bio], WAKE-UP, Dwi, DWI, Brain Ischemia, 0302 clinical medicine, Modified Rankin Scale, therapeutic use [Fibrinolytic Agents], Medicine, complications [Stroke], 030212 general & internal medicine, drug therapy [Depression], Transient ischemic attack, Stroke, Cerebral ischemia -- Treatment, Depression, Atac isquèmic transitori, 3. Good health, drug therapy [Stroke], [SDV] Life Sciences [q-bio], Treatment Outcome, Neurology, Tissue Plasminogen Activator, drug therapy [Brain Ischemia], Life Sciences & Biomedicine, psychological phenomena and processes, Mri, MRI, medicine.medical_specialty, etiology [Depression], Clinical Neurology, Placebo, 03 medical and health sciences, Fibrinolytic Agents, Internal medicine, Post-hoc analysis, mental disorders, Post-stroke depression, Humans, ddc:610, WAKE&#8208, UP, Science & Technology, business.industry, Beck Depression Inventory, Neurosciences, Odds ratio, medicine.disease, Wake-up, nervous system, Isquèmia cerebral -- Tractament, Neurology (clinical), Neurosciences & Neurology, business, 030217 neurology & neurosurgery, Fibrinolytic agent
Abstract

BACKGROUND AND PURPOSE: The aim was to study the effect of intravenous alteplase on the development of post-stroke depression (PSD) in acute stroke patients, and to identify predictors of PSD. METHODS: This post hoc analysis included patients with unknown onset stroke randomized to treatment with alteplase or placebo in the WAKE-UP trial (ClinicalTrials.gov number, NCT01525290), in whom a composite end-point of PSD was defined as a Beck Depression Inventory ≥10, medication with an antidepressant, or depression recorded as an adverse event. Multiple logistic regression was used to identify predictors of PSD at 90 days. Structural equation modelling was applied to assess the indirect effect of thrombolysis on PSD mediated by the modified Rankin Scale. RESULTS: Information on the composite end-point was available for 438 of 503 randomized patients. PSD was present in 96 of 224 (42.9%) patients in the alteplase group and 115 of 214 (53.7%) in the placebo group (odds ratio 0.63; 95% confidence interval 0.43-0.94; p = 0.022; adjusted for age and National Institutes of Health Stroke Scale at baseline). Prognostic factors associated with PSD included baseline medication with antidepressants, higher lesion volume, history of depression and assignment to placebo. While 65% of the effect of thrombolysis on PSD were caused directly, 35% were mediated by an improvement of the mRS. CONCLUSIONS: Treatment with alteplase in patients with acute stroke resulted in lower rates of depression at 90 days, which were only partially explained by reduced functional disability. Predictors of PSD including history and clinical characteristics may help in identifying patients at risk of PSD. ispartof: EUROPEAN JOURNAL OF NEUROLOGY vol:28 issue:6 pages:2017-2025 ispartof: location:England status: published

Published
2021

7. Monocyte CD169 expression in COVID ‐19 patients upon intensive care unit admission

Author

Guillaume Monneret, Thomas Rimmelé, Martin Cour, Fabienne Venet, Rémy Coudereau, Laurent Argaud, Marine Ortillon, Morgane Gossez, Hodane Yonis, Marine Godignon, Anne-Claire Lukaszewicz, Hospices Civils de Lyon (HCL), Hôpital Edouard Herriot [CHU - HCL], Physiopathologie de l'immunodépression associée aux réponses inflammatoires systémiques - EA 7426 (PI3), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Hôpital de la Croix-Rousse [CHU - HCL], Inflammasome NLRP3 et réponse immunitaire au sepsis - NLRP3 inflammasome and immune response to sepsis (NLRP3), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CarMeN, laboratoire, Physiopathologie de l'immunodépression associée aux réponses inflammatoires systémiques / Pathophysiology of Injury-induced Immunosuppression (PI3), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, 0301 basic medicine, Sialic Acid Binding Ig-like Lectin 1, [SDV]Life Sciences [q-bio], Monocytes, law.invention, sepsis, Patient Admission, 0302 clinical medicine, law, Prospective Studies, Brief Report, Middle Aged, Flow Cytometry, Prognosis, Intensive care unit, Up-Regulation, 3. Good health, [SDV] Life Sciences [q-bio], Bacterial sepsis, Intensive Care Units, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Host-Pathogen Interactions, monocyte, Female, Preliminary Data, Adult, medicine.medical_specialty, Histology, Coronavirus disease 2019 (COVID-19), Pathology and Forensic Medicine, 03 medical and health sciences, Predictive Value of Tests, COVID‐19, Intensive care, Internal medicine, medicine, Humans, Aged, SARS-CoV-2, business.industry, Monocyte, COVID-19, Emergency department, Cell Biology, Triage, 030104 developmental biology, CD169, Etiology, business, Biomarkers
Abstract

International audience; During the second surge of COVID-19 in France (fall 2020), we assessed the expression of monocyte CD169 (i.e., Siglec-1, one of the numerous IFN-stimulated genes) upon admission to intensive care units of 45 patients with RT-PCR-confirmed SARS-CoV2 pulmonary infection. Overall, CD169 expression was strongly induced on circulating monocytes of COVID-19 patients compared with healthy donors and patients with bacterial sepsis. Beyond its contribution at the emergency department, CD169 testing may be also helpful for patients' triage at the ICU to rapidly reinforce suspicion of COVID-19 etiology in patients with acute respiratory failure awaiting for PCR results for definitive diagnosis.

Published
2021
Full Text
View/download PDF

8. Ether lipids, sphingolipids and toxic 1‐deoxyceramides as hallmarks for lean and obese type 2 diabetic patients

Author

Jonathan Paz Montoya, Howard Riezman, François R Jornayvaz, Stéphanie Chanon, Flore Sinturel, J. Thomas Hannich, Christine Durand, Zoltan Pataky, Alain Golay, Emmanouil T. Dermitzakis, Maud Robert, Camille Saini, Pauline Gosselin, Ursula Loizides-Mangold, Charna Dibner, Idris Guessous, Marie-Claude Brulhart-Meynet, Jacques Philippe, Takeshi Harayama, Steven A. Brown, Bart Vandereycken, Etienne Lefai, Fabrice P. A. David, Université de Genève = University of Geneva (UNIGE), Institute of Genetics and Genomics in Geneva (iGE3), Geneva University Hospitals and Geneva University, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Université de Lyon, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Ecole Polytechnique Fédérale de Lausanne (EPFL), Universität Zürich [Zürich] = University of Zurich (UZH), Unité de Nutrition Humaine (UNH), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), University of Geneva [Switzerland], Université de Genève (UNIGE), and CarMeN, laboratoire

Subjects
Serum, 0301 basic medicine, endocrine system diseases, Physiology, [SDV]Life Sciences [q-bio], Adipose tissue, Type 2 diabetes, 030204 cardiovascular system & hematology, Mice, 0302 clinical medicine, ddc:590, lipid metabolism, ddc:576.5, ddc:510, visceral adipose tissue, ddc:616, medicine.diagnostic_test, Lipidome, Lipids, 3. Good health, [SDV] Life Sciences [q-bio], Adipose Tissue, Visceral adipose tissue, ddc:540, lipids (amino acids, peptides, and proteins), medicine.medical_specialty, Ether, 03 medical and health sciences, Diabetes mellitus, Internal medicine, Lipidomics, medicine, Animals, Humans, Obesity, ddc:612, ddc:613, Sphingolipids, 1-deoxyceramide, business.industry, nutritional and metabolic diseases, Lipid metabolism, medicine.disease, Sphingolipid, 030104 developmental biology, Endocrinology, Diabetes Mellitus, Type 2, Type 2 diabetes in lean and obese subjects, lipidomics, business, Lipid profile, serum
Abstract

International audience; AIM: The worldwide increase in obesity and type 2 diabetes (T2D) represents a major health challenge. Chronically altered lipids induced by obesity further promote the development of T2D, and the accumulation of toxic lipid metabolites in serum and peripheral organs may contribute to the diabetic phenotype. METHODS: To better understand the complex metabolic pattern of lean and obese T2D and non-T2D individuals, we analysed the lipid profile of human serum, skeletal muscle and visceral adipose tissue of two cohorts by systematic mass spectrometry-based lipid analysis. RESULTS: Lipid homeostasis was strongly altered in a disease- and tissue-specific manner, allowing us to define T2D signatures associated with obesity from those that were obesity independent. Lipid changes encompassed lyso-, diacyl- and ether-phospholipids. Moreover, strong changes in sphingolipids included cytotoxic 1-deoxyceramide accumulation in a disease-specific manner in serum and visceral adipose tissue. The high amounts of non-canonical 1-deoxyceramide present in human adipose tissue most likely come from cell-autonomous synthesis because 1-deoxyceramide production increased upon differentiation to adipocytes in mouse cell culture experiments. CONCLUSION: Taken together, the observed lipidome changes in obesity and T2D will facilitate the identification of T2D patient subgroups and represent an important step towards personalized medicine in diabetes.

Published
2021

9. Biologically plausible trends suggesting that a <scp>low‐protein</scp> diet may enhance the effect of flozination caused by the sodium‐glucose cotransporter‐2 inhibitor dapagliflozin on albuminuria

Author

Denis Fouque, Kamyar Kalantar-Zadeh, Srinivasan Beddhu, Csaba P. Kovesdy, Holly Kramer, CarMeN, laboratoire, University of California [Irvine] (UC Irvine), University of California (UC), Long Beach Medical Center [Long Beach, California, USA] (LBMC), University of Utah, University of Memphis (U of M), Loyola University [Chicago], Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
[SDV]Life Sciences [q-bio], Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Protein-Restricted, Pharmacology, Sodium-Glucose Transporter 2 Inhibitors/therapeutic use, chemistry.chemical_compound, Endocrinology, Glucosides, Low-protein diet, Internal Medicine, medicine, Albuminuria, Humans, Sodium-Glucose Cotransporter 2 Inhibitor, Benzhydryl Compounds, Dapagliflozin, ComputingMilieux_MISCELLANEOUS, Diabetes Mellitus, business.industry, Sodium, Diet, [SDV] Life Sciences [q-bio], Glucose, Type 2/drug therapy, chemistry, medicine.symptom, business
Abstract

International audience; No abstract available

Published
2021

10. Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Author

Lars Johansson, Cyrielle Caussy, CarMeN, laboratoire, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hospices Civils de Lyon (HCL), Antaros Medical AB [Mölndal Sweden] (BioVenture Hub), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)

Subjects
medicine.medical_specialty, elastography, Cirrhosis, Endocrinology, Diabetes and Metabolism, [SDV]Life Sciences [q-bio], Reviews, Review, Disease, Gastroenterology, digestive system, lcsh:Diseases of the endocrine glands. Clinical endocrinology, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, NAFLD, Nonalcoholic fatty liver disease, medicine, magnetic resonance imaging, lcsh:RC648-665, medicine.diagnostic_test, business.industry, hepatic steatosis, NASH, nutritional and metabolic diseases, Magnetic resonance imaging, medicine.disease, Antaros Medical, digestive system diseases, 3. Good health, [SDV] Life Sciences [q-bio], Clinical research, Liver biopsy, Biomarker (medicine), 030211 gastroenterology & hepatology, Steatosis, business
Abstract

Nonalcoholic fatty liver disease is a growing epidemic affecting 30% of the adult population in the Western world. Its progressive form, nonalcoholic steatohepatitis (NASH), is associated with an increased risk of advanced fibrosis, cirrhosis and liver‐related mortality. Therefore, the detection of NAFLD and risk stratification according to the severity of the disease is crucial for the management of patients with NAFLD. Liver biopsy for such risk stratification strategies is limited by its cost and risks; therefore, noninvasive alternatives have been developed. Among noninvasive biomarkers developed in NAFLD, magnetic resonance (MR)‐based biomarkers have emerged as key noninvasive biomarkers in NAFLD with the ability to accurately detect hepatic steatosis and liver fibrosis. The potential utility of MRI for the detection of NASH and functional liver assessment has also recently emerged. In the current review, we will discuss the data supporting the utility of MR‐based biomarker for the detection of features of NAFLD and its potential use in clinical practice and clinical research in NAFLD., This paper reviews the currently available MRI‐based techniques for assessing NAFLD and NASH.

Published
2020

11. Gut microbiota and stroke: New avenues to improve prevention and outcome.

Author

Clottes P, Benech N, Dumot C, Jarraud S, Vidal H, and Mechtouff L

Abstract

Despite major recent therapeutic advances, stroke remains a leading cause of disability and death. Consequently, new therapeutic targets need to be found to improve stroke outcome. The deleterious role of gut microbiota alteration (often mentioned as "dysbiosis") on cardiovascular diseases, including stroke and its risk factors, has been increasingly recognized. Gut microbiota metabolites, such as trimethylamine-N-oxide, short chain fatty acids and tryptophan, play a key role. Evidence of a link between alteration of the gut microbiota and cardiovascular risk factors exists, with a possible causality link supported by several preclinical studies. Gut microbiota alteration also seems to be implicated at the acute phase of stroke, with observational studies showing more non-neurological complications, higher infarct size and worse clinical outcome in stroke patients with altered microbiota. Microbiota targeted strategies have been developed, including prebiotics/probiotics, fecal microbiota transplantation, short chain fatty acid and trimethylamine-N-oxide inhibitors. Research teams have been using different time windows and end-points for their studies, with various results. Considering the available evidence, it is believed that studies focusing on microbiota-targeted strategies in association with conventional stroke care should be conducted. Such strategies should be considered according to three therapeutic time windows: first, at the pre-stroke (primary prevention) or post-stroke (secondary prevention) phases, to enhance the control of cardiovascular risk factors; secondly, at the acute phase of stroke, to limit the infarct size and the systemic complications and enhance the overall clinical outcome; thirdly, at the subacute phase of stroke, to prevent stroke recurrence and promote neurological recovery., (© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results